Neurocrine
Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study
Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks
Neurocrine Biosciences Reports Positive Phase 2 Results for Osavampator in Major Depressive Disorder
Neurocrine Biosciences; osavampator; Phase 2 results; major depressive disorder; AMPA-PAM; SAVITRI study; clinical trial; adjunctive treatment; depression; safety profile
FDA Approves Neurocrine’s Crenessity for Rare Congenital Adrenal Hyperplasia
Neurocrine Biosciences, FDA approval, Crenessity, crinecerfont, congenital adrenal hyperplasia (CAH), rare genetic disease, adrenal gland condition.
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.
Neurocrine Biosciences and Takeda’s Collaborative Drug Shows Promising Results in Phase II Clinical Trial for Depression
Neurocrine Biosciences, Takeda, drug candidate, Phase II clinical trial, depression, promising results.
Neurocrine Biosciences and Takeda’s Collaborative Depression Program Achieves Mid-Stage Success
Neurocrine Biosciences, Takeda, depression program, mid-stage success, clinical trials, mental health, pharmaceutical collaboration.
Neurocrine-Takeda Collaboration Shows Promise in Alleviating Depression Symptoms in Phase 2 Trials
Neurocrine, Takeda, Phase 2 trials, depression, depression severity, medication, analysts, data detail.